Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS.

J Natl Cancer Inst. 2002 Apr 3;94(7):504-13.

PMID:
11929951
2.

Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.

Yu XD, Wang SY, Chen GA, Hou CM, Zhao M, Hong JA, Nguyen DM, Schrump DS.

Cancer J. 2007 Mar-Apr;13(2):105-13.

PMID:
17476138
3.
5.

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.

Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S.

Biochem Pharmacol. 2002 Oct 1;64(7):1079-90.

PMID:
12234611
6.

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.

Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S.

Cancer Lett. 2003 Jun 10;195(2):161-8.

PMID:
12767524
7.

Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.

Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, Guimond M, Marcucci G.

Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2390-8.

PMID:
12766035
9.

Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.

Marcu MG, Schulte TW, Neckers L.

J Natl Cancer Inst. 2000 Feb 2;92(3):242-8.

PMID:
10655441
10.

Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.

Sasaki Y, Negishi H, Idogawa M, Suzuki H, Mita H, Toyota M, Shinomura Y, Imai K, Tokino T.

Mol Cancer Ther. 2008 Apr;7(4):779-87. doi: 10.1158/1535-7163.MCT-07-0395.

11.
12.

Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity.

Kasiappan R, Shih HJ, Chu KL, Chen WT, Liu HP, Huang SF, Choy CO, Shu CL, Din R, Chu JS, Hsu HL.

Mol Cancer Res. 2009 Apr;7(4):536-48. doi: 10.1158/1541-7786.MCR-08-0422.

14.

Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.

Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, Akutsu Y, Sakata H, Matsushita K, Seki N, Ochiai T.

Clin Cancer Res. 2005 Nov 1;11(21):7945-52.

15.

EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.

Kapoor GS, Christie A, O'Rourke DM.

Cancer Biol Ther. 2007 Apr;6(4):571-9.

PMID:
17457042
16.

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R.

Clin Cancer Res. 2003 Mar;9(3):1145-54.

17.

Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.

Sutterl├╝ty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.

Mol Cancer Res. 2007 May;5(5):509-20.

18.

The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation.

Grammatikakis N, Vultur A, Ramana CV, Siganou A, Schweinfest CW, Watson DK, Raptis L.

J Biol Chem. 2002 Mar 8;277(10):8312-20. Epub 2001 Dec 20.

19.

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.

Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB 3rd, Stewart CF, Houghton PJ.

Clin Cancer Res. 2006 Jan 1;12(1):223-34.

Supplemental Content

Support Center